The first infusion of an investigational drug that aims to delay or help to prevent the earliest memory loss due to Alzheimer’s disease took place in September at Butler Hospital in Providence, R.I., researchers announced.
AHEAD 3-45 is a clinical trial for a treatment aimed at preventing cognitive decline in people with preclinical Alzheimer’s Disease (AD).
MAP Director Dr. Stephen Salloway, along with other international leaders in the fight against Alzheimer’s, talk with the Providence Journal and WJAR NBC10 about how the fight to end Alzheimer’s continues despite coronavirus.
Aducanumab, an investigational drug for the treatment for Alzheimer’s disease, has been submitted to the FDA for approval with a request for Priority Review. If approved, it would become the first therapy to reduce the clinical decline of Alzheimer’s disease.
Dr. Daniel Gibbs is on a mission to change attitudes on Alzheimer’s after 13 years living with the disease himself. Here’s the important reason why…
Watch this Alzheimer’s educational video to learn about prevention, symptoms, treatment, resources and research from a panel of Rhode Island experts.
Major Alzheimer’s Association grant to enable researchers to test a drug that could slow the progression of Alzheimer’s disease.
Drug Studied at Butler Hospital’s Memory and Aging Program May Become First New Treatment for Alzheimer’s in 16 Years
Aducanumab maker Biogen seeking FDA review in early 2020; if approved, it will become the first drug to remove amyloid protein from the brain and slow the progression of Alzheimer’s disease (AD).
A look inside the Memory and Aging Program at Butler Hospital and how Southern New Englanders are contributing to the mounting battle against Alzheimer’s.
The results of a landmark trial conducted in part at the Memory and Aging Program at Butler Hospital show that amyloid PET brain scan imaging significantly improves both the accuracy of diagnosis and the subsequent medical management of patients with mild cognitive impairment and dementia.